共 79 条
[1]
Liaw YF(2004)Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 1521-1531
[2]
Sung JJ(2020)Persistent low level of hepatitis b virus promotes fibrosis progression during therapy Clin Gastroenterol Hepatol 18 2591.e6-1199
[3]
Chow WC(2008)HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma Gastroenterology 135 1192-98
[4]
Sun Y(2016)Asian–Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update Hepatol Int 10 1-1908
[5]
Wu X(2015)Present and future therapies of hepatitis B: from discovery to cure Hepatology 62 1893-1599
[6]
Zhou J(2018)Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance Hepatology 67 1560-398
[7]
Yuen MF(2017)Clinical Practice Guidelines on the management of hepatitis B virus infection J Hepatol 2017 370-475
[8]
Wong DK(2013)Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 468-206
[9]
Fung J(2005)Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B J Viral Hepat 12 199-1010
[10]
Sarin SK(2006)A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 1001-893